低剂量替罗非班改善静脉溶栓后早期神经功能恶化结局
本研究回顾性分析2017年1月至2018年9月连续1764例接受静脉溶栓的急性缺血性卒中患者的前瞻性数据。1764例中278例(15.8%)发生早期神经功能恶化,187例符合条件者中121例(64.7%)在溶栓后24小时内接受替罗非班治疗。校正多因素分析显示,早期使用替罗非班与症状性颅内出血、颅内出血和死亡风险无关,但与3个月良好功能结局显著相关。
要点
- 静脉溶栓后24小时内早期神经功能恶化患者使用低剂量替罗非班未增加出血与死亡风险。
- 早期替罗非班使用与3个月优良和良好功能结局显著相关。
- 亚组分析提示替罗非班疗效具有时间依赖性,越早使用可能越有效。
核心结论
- 静脉溶栓后24小时内发生早期神经功能恶化的患者使用低剂量替罗非班未增加症状性颅内出血、颅内出血和死亡风险,似乎与3个月神经功能改善相关。
- 研究者认为未来需要随机临床试验验证这些结果。
研究设计与样本
- 本研究为回顾性分析,数据来自2017年1月至2018年9月连续收集的1764例接受静脉溶栓治疗的急性缺血性卒中患者的前瞻性数据。
- 在静脉溶栓后24小时内发生早期神经功能恶化的患者中,比较接受与未接受替罗非班治疗者的结局;187例符合条件,其中121例(64.7%)接受替罗非班治疗。
主要发现
- 1764例接受静脉溶栓患者中278例(15.8%)发生早期神经功能恶化。
- 校正多因素分析显示,早期使用替罗非班与症状性颅内出血(aOR 1.05;95%CI 0.088-11.02;P=1.000)、颅内出血(aOR 1.13;95%CI 0.45-4.25;P=0.512)和死亡(aOR 0.77;95%CI 0.19-2.27;P=0.875)无显著关联。
- 早期使用替罗非班与优良功能结局(mRS 0-1;aOR 2.24;95%CI 1.16-3.94;P=0.027)和良好功能结局(mRS 0-2;aOR 2.31;95%CI 1.48-3.99;P=0.011)显著相关。
- 亚组分析提示早期替罗非班使用的疗效具有时间依赖性,较早接受替罗非班治疗的患者更有效。
关键数值与推荐
- 早期神经功能恶化定义为静脉溶栓后24小时内发生;1764例中278例(15.8%)发生早期神经功能恶化。
- 疗效结局采用3个月改良Rankin量表评分:优良为0-1分,良好为0-2分。
- 安全性结局包括症状性颅内出血、任何颅内出血、严重系统性出血和死亡。
临床怎么用
- 对静脉溶栓后24小时内发生早期神经功能恶化的急性缺血性卒中患者,可考虑早期使用低剂量替罗非班,但需结合个体出血风险判断。
- 用药时机可能影响疗效,亚组分析提示越早使用可能越有效,但仍需随机临床试验证实。
- 治疗决策应权衡3个月功能结局获益与颅内出血、系统性出血及死亡风险。
局限性
- 本研究为单中心回顾性分析,虽基于前瞻性收集数据,但存在回顾性研究固有局限。
- 替罗非班治疗组与非治疗组非随机分配,可能存在选择偏倚和混杂因素。
- 样本量有限(符合条件187例),亚组分析结果需谨慎解读,结论需未来随机临床试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Early use of antiplatelet drugs within 24 hours after intravenous thrombolysis (IVT) has always been a confusing clinical problem. The purpose of this study was to assess the safety and efficacy of early low-dose tirofiban treatment in patients with early neurological deterioration (END) within the first 24 hours after IVT. Methods- This was a retrospective analysis of prospectively collected data of 1764 consecutive patients with acute ischemic stroke treated with IVT between January 2017 and September 2018. Patients with early neurological deterioration within the first 24 hours after IVT were treated with or without tirofiban. The safety outcomes included symptomatic intracranial hemorrhage, any ICH, severe systemic bleeding, and mortality. Efficacy outcomes included excellent (modified Rankin scale scores 0-1) and favorable (modified Rankin scale scores 0-2) 3-month functional outcomes. Results- Early neurological deterioration occurred in 278 (15.8%) patients. Of the 187 eligible patients, 121 (64.7%) were treated with tirofiban within the first 24 hours after IVT. Adjusted multivariate analysis showed that early tirofiban use was not associated with symptomatic intracranial hemorrhage (adjusted odds ratio [aOR], 1.05; 95% CI, 0.088-11.02; P=1.000), ICH (aOR, 1.13; 95% CI, 0.45-4.25; P=0.512), and mortality (aOR, 0.77; 95% CI, 0.19-2.27; P=0.875) but was significantly associated with excellent (aOR, 2.24; 95% CI, 1.16-3.94; P=0.027) and favorable (aOR, 2.31; 95% CI, 1.48-3.99; P=0.011) functional outcomes. Subgroup analyses suggested that early tirofiban-use efficacy is time dependent, being more effective in patients receiving tirofiban treatment earlier. Conclusions- Low-dose tirofiban use in patients with early neurological deterioration within the first 24 hours after IVT did not increase the risk of symptomatic intracranial hemorrhage, ICH, and mortality, it seems associated with neurological improvement at 3 months. Future randomized clinical trials will be needed to validate these results.
引用
- Wu C, Sun C, Wang L, et al. Low-Dose Tirofiban Treatment Improves Neurological Deterioration Outcome After Intravenous Thrombolysis. Stroke. 2019. PMID: 31570084. doi:10.1161/STROKEAHA.119.026240
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。